1Simonsen,L.The global impact of influenza on morbidity and mortality. Vaccine . 1999
2Taubenberger J K,Reid A H,Lourens R M,et al.Characterization of the 1918 influenza virus polymerase genes. Nature . 2005
3Yoshida R,Igarashi M,Ozaki H,et al.Cross-protective poten-tial of a novel monoclonal antibody directed against antigenic siteB of the hemagglutinin of influenza Aviruses. PLoS Pathog . 2009
1NEUMANN G, N ODA T, KAWAOKA Y. Emergence and pandemic potential of swine-origin HIN 1 influenza virus[J]. Nature, 2009, 459(7249): 931-9.
2SUN X, TSE LV, FERQUSON AD, et al. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic HINI influenza virus[J]. J Virol, 2010, 84(17): 8683-8690.
3BOSCH B J, BODEWEA R, DE VRIES RP, et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types orprotection against pandemic swine-origin 2009 A(H 1N 1 ) influenza virus infection in ferrets[J]. J Virol, 2010, 84( 19): 10366-10374.
4DUNHAM E J, DUQAN VG, KASER EK, et al. Different evolutionary trajectories of european Avian-like and classical swine H1N1 influenza A viruses[J]. J Virol, 2009, 83(11): 5485-5494.
5AUDSLEY J M, TANNOCK G A. The role of cell culture vaccines in the control of the next influenza pandemic[J]. Expert Opin Biol Ther, 2004, 4: 709-717.
6ZAMBON M. Cell culture for surveillance of influenza[J]. Dev Biol Stand, 1999, 98: 65-71.
7SCHILD G C, OXFORD J S, DE JONG J C, et al. Evidence for host-cell selection of influenza virus antigenic variants[J]. Nature, 1983, 303: 706-709.
8KISTNER O, BARRETT PN, MUNDT W, et al. Development ofa mammaliancel (Vero)dcrived cadidate influenza virus vaccine[J]. Vaccine, 1998, 16: 960-968.
9GENZEL Y, REICHL U. Continuous cell lines as a production system for influenza vaccines. Expert Rev[J]. Vaccines, 2009, 8: 1681-1692.
10CRISTIAN PAILLET, GUILLERMINA FORNO, NICOLAS SOLDSNO, et al. Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero)[J]. Vaccine 29, 2011: 7212-7217.
